We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
- Cancer/Oncology
-
2. Cancer vaccines
- Dr. Elias Sayour
-
3. The future of blood tests in cancer treatment
- Dr. Isaac Garcia-Murillas
-
5. Artificial intelligence in precision medicine
- Dr. Michael P. Menden
-
6. How liver X receptor regulates intestinal regeneration and tumor growth
- Dr. Srustidhar Das
- Neurology/Neuroscience
-
7. Integrated multimodal cell atlas of Alzheimer’s disease
- Dr. Michael Hawrylycz
-
8. How and why neurons die in Alzheimer's disease?
- Prof. Bart De Strooper
-
9. Restoring glucose metabolism: a new approach to reversing cognitive decline in AD
- Prof. Katrin Andreasson
-
10. Advancing ALS genetics through accessible testing
- Dr. Teresa Fecteau
-
11. MicroRNA as a biomarker for early detection of amyotrophic lateral sclerosis
- Dr. Sandra Banack
- Dr. Paul Alan Cox
- Dr. Rachael Dunlop
-
12. Translational research in amyotrophic lateral sclerosis (ALS)
- Prof. Aaron D. Gitler
-
13. Muscarinic acetylcholine receptor modulation in neurological diseases- Prof. Andrew B. Tobin
- Immunology & Inflammation
-
14. Role of ETS2 in autoimmune and inflammatory diseases
- Dr. James Lee
-
15. Rheumatic diseases and musculoskeletal pain
- Prof. Anisur Rahman
-
16. Decoy-resistant IL18: how engineered E. coli enhances immune responses against tumors- Dr. Rizwan Romee
-
17. Transmembrane domains and the regulation of trogocytosis in T cells
- Dr. Stefano Barbera
- Infectious Diseases/Microbiology
-
20. Elite controllers of HIV: from discovery to future therapies
- Prof. Bruce Walker
-
22. Towards developing a universal influenza vaccine
- Prof. Peter Palese
- Pharmaceutical Sciences
-
23. The state of the art in secondary pharmacology
- Dr. Jean-Pierre Valentin
-
24. The safety, toxicology, and regulation of antibody-drug conjugates
- Dr. Veysel Kayser
-
26. Management of generic drug development: challenges and opportunities
- Mr. Sandeep Patil
-
27. Translational medicine: the risk of failure in delay and how to reduce it
- Prof. Martin Wehling
-
28. The regulation of cell therapy
- Prof. Moutih Rafei
-
29. Scale-up challenges in the production of nanomedicines from lab to industry
- Prof. Dr. Oya Tagit
-
30. Challenges and solutions of scaling up
- Dr. Shaukat Ali
-
32. Using real-world insights on drug interactions to inform drug development
- Dr. Amita Datta-Mannan
-
33. Role of marketing authorization holder in drug safety
- Dr. Raphael Elmadjian Pareschi
- Methods
-
34. The role of preregistration and registered reports in improving research transparency and reproducibility
- Dr. Peter Bonde Ernst-Rasmussen
-
35. Decoding aging: how a proteomic clock predicts mortality and disease across populations
- Dr. M. Austin Argentieri
-
36. MassBank development and future
- Dr. Emma L. Schymanski
-
37. Synthetic whole embryo models and their applications
- Prof. Jacob (Yaqub) Hanna
-
38. Pioneering proteomics: insights on advancements in the science of proteins
- Prof. Ruedi Aebersold
Topics Covered
- Medical Affairs Professional Society (MAPS)
- R&D
- Commercialization
- Strategic leadership
- Pharmaceutical industry
- Funding
- Patient care
- Industry partnership program
- Health equity
- DEI
- ESG
- Affordability
- Ethics
- Professional standards
- Unmet needs
- Patient outcomes
- Real world evidence
- Healthcare system
- Medical affairs profession
Biography
Danie is currently EVP, Medical Affairs at Kyowa Kirin and Chair of the Medical affairs Professional Society (MAPS) board. He is a senior pharmaceutical executive with 30 years’ experience mainly in Medical Affairs. He has a passion for modernising medical affairs and track record in leadership, people development, capability building and coaching. Danie is a qualified MD with a Masters in Clinical Pharmacology who combines medical and life science qualifications with an MBA. Danie has extensive experience building international teams, driving change and working in regulated markets for GlaxoSmithKline (GSK) across Europe, the Americas, Middle East, Africa, Australasia and Japan. He previously worked for Eli Lilly & Company for 17 years in different medical roles as well as marketing and sales. During his different roles, he was based in South Africa, United Kingdom and Australia. Before joining the Pharmaceutical Industry, Danie had his own primary care practice.
Talk Citation
du Plessis, D. (2023, September 28). MAPS: the business of medical affairs [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved February 18, 2026, from https://doi.org/10.69645/DQIU1834.Export Citation (RIS)
Publication History
- Published on September 28, 2023
Financial Disclosures
- Dr. Danie du Plessis has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.